Grünberger W, Parschalk O, Fischl F
Med Klin. 1981 Apr 24;76(9):257-60.
A prospective study 30 out of 60 pregnant women suffering from pathologic hypotension were treated regularly with the mineralocorticoid 11-Desoxycorticosteronönanthat (Cortiron (R)-Depot). To the other 30 women no medication was given --they served as a control-group. In order to get information on the uteroplacental perfusion rate, placental flow measurements using radioisotopes were carried out. In comparison with the untreated blood-pressure and placental perfusion in the medicated pregnant women was significantly higher. The investigation of the fetal outcome showed 600 g heavier neonates in the mineralocorticoid treated group; the rate of dystrophy was significantly lower. The results entitle the requirement of medication in cases of maternal hypotension (RR 110/65 mm Hg and below). By our experiences we can recommend the mineralocorticoid Cortiron (R)-Depot.
一项前瞻性研究中,60名患有病理性低血压的孕妇中有30名定期接受盐皮质激素11 - 去氧皮质酮壬酸酯(考的索长效注射液)治疗。另外30名女性未接受任何药物治疗,作为对照组。为了获取子宫胎盘灌注率的信息,使用放射性同位素进行了胎盘血流测量。与未治疗组相比,接受药物治疗的孕妇血压和胎盘灌注显著更高。对胎儿结局的调查显示,盐皮质激素治疗组的新生儿体重重600克;营养不良发生率显著更低。研究结果表明,对于母亲低血压(收缩压/舒张压为110/65毫米汞柱及以下)的情况需要进行药物治疗。根据我们的经验,我们推荐使用盐皮质激素考的索长效注射液。